Phase II and Pharmacokinetic Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2015
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Nov 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 23 Nov 2011 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.